Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

523 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART).
Mata N, Alonso R, Badimón L, Padró T, Fuentes F, Muñiz O, Perez-Jiménez F, López-Miranda J, Díaz JL, Vidal JI, Barba A, Piedecausa M, Sanchez JF, Irigoyen L, Guallar E, Ordovas JM, Mata P. Mata N, et al. Lipids Health Dis. 2011 Jun 10;10:94. doi: 10.1186/1476-511X-10-94. Lipids Health Dis. 2011. PMID: 21663647 Free PMC article.
Clinical decisions in patients with diabetes and other cardiovascular risk factors. A statement of the Spanish Society of Internal Medicine.
Gómez-Huelgas R, Pérez-Jiménez F, Serrano-Ríos M, González-Santos P, Román P, Camafort M, Conthe P, García-Alegría J, Guijarro R, López-Miranda J, Tirado-Miranda R, Valdivielso P; SEMI Working Group; Spanish Society of Internal Medicine. Gómez-Huelgas R, et al. Rev Clin Esp (Barc). 2014 May;214(4):209-15. doi: 10.1016/j.rce.2013.12.014. Epub 2014 Mar 3. Rev Clin Esp (Barc). 2014. PMID: 24602600 English, Spanish.
Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation.
Alonso R, Andres E, Mata N, Fuentes-Jiménez F, Badimón L, López-Miranda J, Padró T, Muñiz O, Díaz-Díaz JL, Mauri M, Ordovás JM, Mata P; SAFEHEART Investigators. Alonso R, et al. J Am Coll Cardiol. 2014 May 20;63(19):1982-9. doi: 10.1016/j.jacc.2014.01.063. Epub 2014 Mar 13. J Am Coll Cardiol. 2014. PMID: 24632281 Free article.
[Consensus document of the Spanish Society of Arteriosclerosis on indications of inhibitors of PCSK9].
Masana L, Ascaso JF, Civeira F, Pedro-Botet J, Valdivielso P, Guijarro C, Mostaza J, López Miranda J, Pintó X; en nombre de la Sociedad Española de Arteriosclerosis. Masana L, et al. Clin Investig Arterioscler. 2016 May-Jun;28(3):164-5. doi: 10.1016/j.arteri.2016.02.001. Epub 2016 Mar 11. Clin Investig Arterioscler. 2016. PMID: 26976748 Spanish. No abstract available.
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS; FOURIER Investigators. Giugliano RP, et al. Lancet. 2017 Oct 28;390(10106):1962-1971. doi: 10.1016/S0140-6736(17)32290-0. Epub 2017 Aug 28. Lancet. 2017. PMID: 28859947 Free article. Clinical Trial.
523 results